← All trials
NCT03676322
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 18, 2018
- Primary completion
- Apr 15, 2019
- Completion date
- Apr 15, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 104
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Merck KGaALead sponsor
- Merck KGaAStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.